Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Videos|June 17, 2025

BIO 2025: Considerations for Drug Development

Author(s)Susan Haigney

BioPharm International® spoke with Robert Cornog, senior director, Product Development, at Quotient Sciences about how commercial manufacturing and tech transfer impact biopharmaceuticals at the development stage.

Developing a biopharmaceutical includes multiple steps and a variety of factors that must be taken into consideration. While commercial manufacturing and tech transfer may seem far downstream in the process from development, they are actually important parts of the formulation process.

“A great example is with the selection of raw materials and alignment with global compendia,” explains Robert Cornog, senior director, Product Development, at Quotient Sciences. “You want to avoid any divergence in acceptance between regions, which could lead to reformulation down the lines. At Quotient, we start assessing scalability and intended control strategies as soon as possible, while still building in flexibility wherever you can for the program, so you can pivot when those changes are needed. And those needs and those changes will most certainly occur throughout a program's lifecycle as you start to approach commercialization. Engaging with your regulatory groups early to align on your filing strategies and your CMC [chemistry, manufacturing, and controls] control strategies [will] avoid any unknown misalignments down the road which could cause additional hurdles in your filings.”

Click the video above to watch the full interview.

Quotient Sciences can be found at Booth #3084 at the BIO International Convention happening from June 16–19 in Boston.

About the speaker

Robert Cornog is senior director, Product Development, at Quotient Sciences.


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.